Moneycontrol PRO
Upcoming Event:Attend Algo Convention Live, 2 Days & 12+ Speakers at best offer Rs.999/-, exclusive for Moneycontrol Pro subscribers. Register now!

COVID-19 vaccine | UNICEF signs supply agreement with Russian Direct Investment Fund for Sputnik V

Procurement by UNICEF under this agreement is conditional on the product achieving an Emergency Use Listing from WHO, to confirm the quality, safety and efficacy of the vaccine.

May 27, 2021 / 08:45 PM IST
Representative image of the Russian Sputnik V COVID-19 vaccine

Representative image of the Russian Sputnik V COVID-19 vaccine


UNICEF and the Russian Direct Investment Fund (RDIF), on May 27 announced a long-term agreement (LTA) for the supply of the Sputnik V COVID-19 vaccine.

This is the fourth long-term supply agreement UNICEF has signed with a COVID-19 vaccine manufacturer. So far this year, UNICEF has signed such agreements with the Serum Institute of India, Pfizer and AstraZeneca.

Procurement by UNICEF under this agreement is conditional on the product achieving an Emergency Use Listing from WHO, to confirm the quality, safety and efficacy of the vaccine.

In addition, an Advance Purchase Agreement (APA) with Gavi, the Vaccine Alliance, will also be needed for procurement to begin on behalf of the COVAX Facility. Should the COVAX Facility decide to enter into an advance purchase agreement for the supply of the Sputnik V vaccine, UNICEF will be ready to deliver as soon as regulatory milestones have been met.

"At this point, UNICEF through this LTA, stands ready to access up to 220 million doses of the vaccine available for supply in 2021, to meet country demand," UNICEF said in a statement.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The Sputnik V vaccine consists of two different components of the vaccine to be administered 21 days apart. An exact delivery schedule will be determined in collaboration with the manufacturer.

"UNICEF’s priority is to make sure that all countries have safe, fast and equitable access to COVID-19 vaccine and to help them prepare for the rollout of immunization," the UN body said.

"The best way to bring the pandemic under control is to ensure that safe and effective vaccines are made available as widely as possible and as quickly as possible, reducing inequity by ensuring that no country or territory is left behind due to its economic status," it added.

About 70 percent of the global supplies of Sputnik V vaccines will be supplied by Indian manufacturers. RDIF has tied up with six Indian drug makers to manufacture and supply the vaccine.



Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: May 27, 2021 08:45 pm
Sections
ISO 27001 - BSI Assurance Mark